NSPR
Q4 2026 EPS Estimate
$-0.15
Nov 10, 2026 · Reports before open
Revenue Estimate
$2M

Analyst Sentiment

Wall St. Consensus
Buy
6 analysts·Limited coverage
75
Score
6 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
6100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$3.00
+292.1%
Consensus
$3.50
+357.4%
Bull
$4.00
+422.7%
12-Month Target Range6 analysts
$3.00$3.50$4.00
Current $0.77Consensus
Current Price
$0.77
Upside to Consensus
$2.73

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+105.44%
EPS
FY2028
Rev-4.48%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$10M$20M$19M
Low$9M$18M$17M
High$11M$23M$22M
EBITDA Avg$-52M$-36M
Low$-53M$-41M
High$-39M$-30M
EBIT Avg$-53M$-37M
Low$-53M$-42M
High$-40M$-31M
Net Income Avg$-53M$-37M
Low$-53M$-42M
High$-40M$-31M
EPS Avg$-0.61$-0.48
Low$-0.72$-0.57
High$-0.54$-0.42
Analysts (Rev / EPS)2 / 12 / 21 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$2M$3M$3M$4M$5M$9M
Low$2M$2M$3M$4M$5M$8M
High$2M$3M$4M$4M$6M$9M
EBITDA Avg$-11M$-9M$-7M$-8M$-9M$-11M
Low$-12M$-10M$-8M$-8M$-9M$-12M
High$-10M$-9M$-7M$-7M$-8M$-11M
EBIT Avg$-11M$-10M$-7M$-8M$-9M$-12M
Low$-12M$-10M$-8M$-8M$-10M$-13M
High$-10M$-9M$-7M$-7M$-8M$-11M
Net Income Avg$-11M$-10M$-7M$-8M$-9M$-12M
Low$-12M$-10M$-8M$-8M$-10M$-13M
High$-10M$-9M$-7M$-7M$-8M$-11M
EPS Avg$-0.15$-0.13$-0.10$-0.10$-0.12$-0.16
Low$-0.17$-0.14$-0.11$-0.11$-0.13$-0.17
High$-0.14$-0.12$-0.09$-0.10$-0.11$-0.15
Analysts (Rev / EPS)2 / 22 / 21 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

May 5, 2026Piper Sandler
InspireMD price target lowered to $3 from $4 at Piper Sandler
Target:$3.00
+156.4%from $1.17
May 4, 2026Lake Street
InspireMD price target lowered to $4 from $5 at Lake Street
Target:$4.00
+240.4%from $1.18
Feb 24, 2026Loop Capital Markets
Lake Street Capital Markets Reiterates Buy Rating on InspireMD (NSPR)
Target:$5.00
+174.7%from $1.82
Feb 2, 2026Maxim Group
InspireMD initiated with a Buy at Maxim
Target:$6.00
+257.2%from $1.68
Dec 11, 2024Lake Street
InspireMD initiated with a Buy at Lake Street
Target:$5.00
+57.7%from $3.17
Sep 17, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on InspireMD (NSPR)
Target:$4.50
+72.4%from $2.61
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.